This is a momentous day for Provectus and a significant step forward for those cancer patients and their families who will be helped by PV-10. It is a tribute to the vision, determination and hard work of Management.
And it really is only the beginning.
There are celebrations in many quarters tonight and I hope all the shareholders, determined to be invested through the endgame, feel renewed conviction tonight.
Provectus Biopharmaceuticals Inc. to List on NYSE MKT
Tuesday May 13, 2014
Common Shares to Begin Trading on Friday May 16, 2014
Symbol Remains "PVCT"
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), announced today that its shares of common stock have been approved for listing on the NYSE MKT. Shares will begin trading on the NYSE MKT on Friday May 16, 2014. The company's ticker symbol will remain "PVCT" but it will withdraw its shares from quotation on the OTCQB concurrent with listing its shares on the NYSE MKT.
Dr. Craig Dees, PhD, CEO of Provectus said, "Listing on the NYSE MKT is a huge milestone for Provectus Biopharmaceuticals, and I take a great deal of personal satisfaction from this news. I believe that this will enhance our shareholder value as well as broaden our shareholder base and heighten our corporate profile in the capital markets."
NYSE MKT is a fully integrated trading venue within the NYSE Euronext community and leverages the NYSE's advanced and innovative market model to offer a premier venue for listing and trading the stocks of small companies. The venue utilizes the trading, connectivity and routing technologies of the NYSE platform and offers superior price discovery, superior liquidity and reduced trading volatility. Listed companies benefit from issuer-selected Designated Market Makers (DMM) that utilize world-class NYSE trading systems to discover and improve prices, dampen volatility, add liquidity and enhance value. In addition, NYSE MKT-listed companies gain access to the brand visibility and are eligible for the issuer services enjoyed by the NYSE Euronext community.
"We welcome Provectus to the NYSE community and look forward to a strong partnership with the Company and its shareholders," said Scott Cutler, Executive Vice President and Head of Global Listings at NYSE Euronext. "Provectus will join other pharmaceutical companies that benefit from NYSE's trusted and reliable platform to raise capital."
The complete press release is available at www.pvct.com/pressrelease.html?article=20140513 on the Provectus website.
Disclosure: I am long PVCT.